Evidence-based·Last reviewed May 30, 2026·How we grade evidence

Tesamorelin

PeptidePeptide drug

Useful mainly for adults with HIV-associated lipodystrophy and excess visceral abdominal fat.

Prescription medication — not a dietary supplement

This is an FDA-approved (or investigational) drug, not a supplement. It requires a prescription and medical supervision. The information below summarizes clinical-trial evidence for education only — it is not a recommendation to obtain or use it without a doctor.

Quick decision guide

May help most

Adults with HIV-associated lipodystrophy and excess visceral abdominal fat

Common dosing range

2 mg subcutaneously once daily

When to expect effects

Weeks to months (visceral fat reduction measurable by ~3-6 months)

Watch out for

Not approved for general weight loss or bodybuilding; raises IGF-1 and is contraindicated in active malignancy

What is it

Tesamorelin is a synthetic analog of growth-hormone-releasing hormone (GHRH) given by daily subcutaneous injection. It stimulates the pituitary to release endogenous growth hormone, which in turn raises IGF-1 and reduces visceral fat. It is FDA-approved to reduce excess abdominal fat (lipodystrophy) in adults living with HIV.

Is it worth it for you?

Use this as a quick fit check, not a diagnosis.

Worth considering if…

You are an adult with HIV and clinically significant excess visceral abdominal fat, prescribed and monitored by a clinician
You can commit to daily subcutaneous injections and periodic IGF-1 monitoring
Your visceral fat persists despite stable antiretroviral therapy

Probably skip if…

You want a general weight-loss drug or cosmetic body recomposition (not its indication and benefit reverses on stopping)
You have active or suspected malignancy
You are pregnant, or have disruption of the hypothalamic-pituitary axis from tumor, surgery, radiation, or head trauma

Evidence at a glance

hiv-associated lipodystrophy (excess visceral abdominal fat)

Strong Evidence
Effect
Roughly 15-18% reduction in visceral adipose tissue versus placebo over 26 weeks
Best fit
Adults with HIV and increased visceral abdominal fat on stable antiretroviral therapy
Time
Weeks to months

Evidence for 1 use

AI-assisted evidence assessment — talk to your doctor before relying on any single supplement.

hiv-associated lipodystrophy (excess visceral abdominal fat)

Disease adjunct
Strong Evidence

Two phase-3 randomized, double-blind, placebo-controlled trials in adults with HIV and excess abdominal fat showed that 2 mg daily subcutaneous tesamorelin reduced CT-measured visceral adipose tissue by approximately 15-18% relative to placebo over 26 weeks, with continued benefit through 52 weeks in extension. Waist circumference and triglycerides also improved. Visceral fat re-accumulated after the drug was stopped, indicating ongoing therapy is needed to sustain the effect.

Effect size
Roughly 15-18% reduction in visceral adipose tissue versus placebo over 26 weeks
Time to effect
Weeks to months
Best fit
Adults with HIV and increased visceral abdominal fat on stable antiretroviral therapy

Bottom line: Daily tesamorelin meaningfully reduces excess visceral abdominal fat in HIV-associated lipodystrophy, but only while treatment continues.

SourceBadran et al., 2026 — PubMedRusso et al., 2024 — PMC

How to take it

1. Typical dose
2 mg (delivered as labeled, e.g. Egrifta SV 1 mg/1.5 mg reconstituted) subcutaneously once daily, prescribed by a clinician
2. Timing
Once daily; rotate injection sites on the abdomen
3. With food
Independent of food; administered subcutaneously, not orally
4. How long to try
Continued use is required to maintain effect; visceral fat re-accumulates after discontinuation, so the prescriber reassesses ongoing need

What to track

Visceral adipose tissue / waist circumference
Serum IGF-1 (to avoid sustained supraphysiologic levels)
Fasting glucose and HbA1c (glucose tolerance can worsen)
Injection-site reactions

Safety

Know the common side effects, key cautions, and who should avoid it.

Common side effects

Injection-site reactions (redness, itching, pain, bruising)Joint pain (arthralgia) and muscle painPeripheral edema and fluid retentionCarpal tunnel-type symptomsFlushing or rash

Serious risks

  • Elevated IGF-1, with theoretical concern for promoting neoplasia; contraindicated in active malignancy

  • Worsening glucose tolerance / new or worsened diabetes

  • Hypersensitivity and rare anaphylaxis

  • Fluid retention that may exacerbate heart failure

Who should avoid it

  • People with active or suspected malignancy
  • People with disruption of the hypothalamic-pituitary axis (pituitary tumor, surgery, head radiation, or trauma)
  • Pregnant individuals
  • Anyone with hypersensitivity to tesamorelin or mannitol

Pregnancy & breastfeeding

Contraindicated in pregnancy — the benefit (fat reduction) provides no therapeutic value in pregnancy and IGF-1 elevation poses fetal risk.

Interactions

Insulin and oral antidiabetic drugsModerate

Tesamorelin can raise glucose and reduce insulin sensitivity, potentially requiring antidiabetic dose adjustment

Drugs metabolized via CYP450 (e.g. some statins, antiepileptics)Moderate

Restoring GH/IGF-1 can alter CYP-mediated metabolism of co-administered drugs

Glucocorticoids / cortisone replacementModerate

GH affects cortisol conversion (11-beta-HSD), which may unmask cortisol insufficiency or require steroid dose changes

Choosing a product

What to look for on the label — and what to be skeptical of.

Look for…

Only obtain via a licensed prescriber and pharmacy as FDA-approved Egrifta / Egrifta SV
Supplied as a sterile lyophilized powder for reconstitution with proper diluent
Dispensed with clinician instruction on subcutaneous injection technique and IGF-1 monitoring

Be skeptical of…

Grey-market or 'research-only' tesamorelin vials sold for bodybuilding or anti-aging
Compounded or unverified peptide blends promising fat loss without a prescription
Any source implying it is a general weight-loss supplement

References by claim

hiv-associated lipodystrophy (excess visceral abdominal fat)

Badran et al., 2026 — PubMed (2026) link

Russo et al., 2024 — PMC (2024) link

Track Tesamorelin with Pilora

Set up dose reminders, check interactions, and join the community in the Pilora iPhone app.

Coming to App Store
Evidence-based·Last reviewed May 30, 2026·Evidence current as of May 30, 2026·How we grade evidence

Disclaimer: This page summarizes published clinical-trial data for educational purposes and is not medical advice or a recommendation to use this prescription medication. Dosing, eligibility, and monitoring must be decided by a licensed prescriber.